Dr. Joël Doré
Joël Doré is Research Director at the French National Institute for Research in Agriculture, Food and the Environment INRAE. He is Scientific Director of the center of excellence MetaGenoPolis, a Unit of the Micalis Institute “Food and Gut Microbiology for Human Health” (mixed research unit associated INRAE, AgroParisTech and Université Paris-Saclay).
Joël Doré also chairs the expert group of the scientific web-platform www.gutmicrobiotaforhealth.com. Finally, he is scientific advisor for MaaT Pharma (www.maatpharma.com), a startUp developing innovative microbiotherapy solutions designed to restore man-microbes symbiosis in cancer therapy.
- Chairman of the expert group of the scientific web-platform www.gutmicrobiotaforhealth.com
- Scientific advisor for MaaT Pharma (www.maatpharma.com)
- Corresponding member of French Academy of Agriculture
- Scientific board member of Medical School of University Paris-Saclay
Joël Doré is Research Director at the French National Institute for Research in Agriculture, Food and the Environment INRAE. He is Scientific Director of the center of excellence MetaGenoPolis, a Unit of the Micalis Institute “Food and Gut Microbiology for Human Health” (mixed research unit associated INRAE, AgroParisTech and Université Paris-Saclay).
Joël Doré also chairs the expert group of the scientific web-platform www.gutmicrobiotaforhealth.com. Finally, he is scientific advisor for MaaT Pharma (www.maatpharma.com), a startUp developing innovative microbiotherapy solutions designed to restore man-microbes symbiosis in cancer therapy.
- Chairman of the expert group of the scientific web-platform www.gutmicrobiotaforhealth.com
- Scientific advisor for MaaT Pharma (www.maatpharma.com)
- Corresponding member of French Academy of Agriculture
- Scientific board member of Medical School of University Paris-Saclay
Joël Doré has been working on microbiota for 38 years. He is an internationally recognized leader in human microbiota.
Joël Doré, Graduated of Agro Rennes, with a Master of Advanced Studies in Applied Animal Physiology. He joined INRA in Clermont-Ferrand in 1983. Then he received his PhD from the University of Illinois at Urbana-Champaign, USA, in 1988, with a thesis on the rumen microbiota, completed while he was contractual scientific associate at INRA. His research on human microbiota started when he joined Inrae Center at Jouy-en-Josas, in 1990. From 2010 until 2014, he was vice-head of MICALIS, one of the largest units of INRA (now INRAE: French National Institute for Research in Agriculture, Food and the Environment).
He is now Scientific Director of MetaGenoPolis, an INRAE unit created in 2012 and funded by the French program “Investissements d’Avenir”. Its expertise in the analysis of the gut microbiome and its implications in health and nutrition has been widely recognized in the international scientific community. Joël Doré aims to contribute to a better understanding of the human-microbes symbiosis to support therapeutic choices, in the medical area as well as science-based recommendations in health nutrition.
He is vice president of the Gut Microbiota for Health section of ESNM and chairs the expert group of the scientific web-platform www.gutmicrobiotaforhealth.com, Finally he is scientific advisor for MaaT Pharma (www.maatpharma.com), a StartUp founded in 2014, developing safe and standardized innovative microbiotherapy solutions designed to restore man-microbes symbiosis in treatment-related dysbiosis.
In 2019, Joël Doré’s project “Homo symbiosus” was selected for an ERC-Advanced grant. This project aims to “evaluate, preserve and restore the human-microbe symbiosis” and addresses Human health with a systemic and global vision, centered on the relationship between human and his microbes.
Micalis: https://www.micalis.fr/micalis_eng/Micalis-Institute
MetaGenoPolis: https://mgps.eu/
Malard F. et al.
Introduction to host microbiome symbiosis in health and disease.
Mucosal Immunol. 2021 May;14(3):547-554
https://pubmed.ncbi.nlm.nih.gov/33299088/
Van de Guchte M. et al.
Alternative stable states in the intestinal ecosystem: proof of concept in a rat model and a perspective of therapeutic implications.
Microbiome. 2020 Nov 6;8(1):153.
https://pubmed.ncbi.nlm.nih.gov/33158453/
Tauzin A-S. et al.
Investigating host-microbiome interactions by droplet based microfluidics.
Microbiome. 2020 Oct 1;8(1):141.
https://pubmed.ncbi.nlm.nih.gov/33004077/
Kumar Dogra S. et al.
Gut Microbiota Resilience: Definition, Link to Health and Strategies for Intervention.
Front Microbiol. 2020 Sep 15;11:572921.
https://pubmed.ncbi.nlm.nih.gov/33042082/
Duquenoy A. et al.
Assessment of Gram- and Viability-Staining Methods for Quantifying Bacterial Community Dynamics Using Flow Cytometry.
Front Microbiol. 2020 Jun 26;11:1469
https://pubmed.ncbi.nlm.nih.gov/32676069/
Al Assal K. et al.
Gut Microbiota Profile of Obese Diabetic Women Submitted to Roux-en-Y Gastric Bypass and Its Association with Food Intake and Postoperative Diabetes Remission.
Nutrients. 2020 Jan 21;12(2):278.
https://pubmed.ncbi.nlm.nih.gov/31973130/
Sunagawa S. et al.
Metagenomic species profiling using universal phylogenetic marker genes.
Nat Methods. 2013 Dec;10(12):1196-9
https://pubmed.ncbi.nlm.nih.gov/24141494/
Qin J. et al.
A human gut microbial gene catalogue established by metagenomic sequencing.
Nature. 2010 Mar 4;464(7285):59-65
https://pubmed.ncbi.nlm.nih.gov/20203603/
Tap J. et al.
Towards the human intestinal microbiota phylogenetic core.
Environ Microbiol. 2009 Oct;11(10):2574-84.
https://pubmed.ncbi.nlm.nih.gov/19601958/
Sokol H. et al.
Specificities of the fecal microbiota in inflammatory bowel disease.
Inflamm Bowel Dis. 2006 Feb;12(2):106-11.
https://pubmed.ncbi.nlm.nih.gov/16432374/
Dr. Joël Doré’s Microbiota Events
The impact of antibiotics in the microbiota ecosystem.
